Skip to content
The Policy VaultThe Policy Vault

Danziten — CareFirst (Caremark)

Myeloid/Lymphoid Neoplasms with Eosinophilia and ABL1 rearrangement

Initial criteria

  • Diagnosis of myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

Initial and continuation 12 months